Baxalta now part of Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Baxalta now part of Shire sits in the top decile of US sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count).
Baxalta now part of Shire: 74 sponsored US clinical trials, 1 recruiting.
Baxalta now part of Shire sponsors 74 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 58 completed. 34 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia A, with 4 trials.
Top-decile sponsor footprint
Baxalta now part of Shire ranks in the top decile of sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 71 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
74 total, page 2 of 2
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
NCT00818662
Gammagard Liquid and rHuPH20 in PID
NCT00814320
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
NCT00816660
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
NCT00666263
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
NCT00952822
A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly
NCT00333528
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
NCT00546871
Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously
NCT00333515
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
NCT00782106
Aralast alpha1-proteinase Inhibitor Surveillance Study
NCT00313144
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
NCT00357656
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
NCT00161720
ADVATE Post Authorization Safety Surveillance
NCT00214734
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
NCT00157157
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
NCT00157092
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
NCT00157118
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
NCT00161707
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
NCT00157079
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
NCT00157040
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
NCT00157105
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
NCT00003056
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 11 |
| Phase 3 | 29 |
| Phase 4 | 5 |
What is open in the Baxalta now part of Shire pipeline
1 recruiting of 74 indexed (1% open); 58 completed (78%).
Phase mix: 34 late (III/IV) vs 26 early (I/II) (balanced across stages).
Top condition: Hemophilia A (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baxalta now part of Shire: open-pipeline peers nationwide
Peers matched on 74 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Baxalta now part of Shire sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 74 trials (± recruiting share)
- C. R. Bard · 75 trials · 5% recruiting
- ECOG-ACRIN Cancer Research Group · 75 trials · 16% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Astellas Pharma · 1% recruiting · 165 trials
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Baxalta now part of Shire page
74 registered trials is a research-attention snapshot, not an endorsement of Baxalta now part of Shire or any single study.
- 1 of Baxalta now part of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hemophilia A is the condition Baxalta now part of Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemophilia A trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Baxalta now part of Shire pipeline card: 74 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.